What is the domestic price and medical insurance policy of pazopanib?

Pazopanib is a multi-target tyrosine kinase inhibitor that is widely used in the treatment of advanced renal cell carcinoma or soft tissue sarcoma. In recent years, its accessibility in the Chinese market has also increased significantly. According to current domestic policies, the original drug of pazopanib is produced by Novartis with the trade name Votrient. It has been officially approved to enter the Chinese market and has been included in the national medical insurance directory. According to the updated policy of the National Medical Insurance Administration, pazopanib can be used as first-line treatment for patients with advanced renal cell carcinoma, especially those who have failed cytokine therapy. Its medical insurance coverage must meet specific indications and meet the doctor's prescription standards in order to enjoy the overall reimbursement of medical insurance.

From a price point of view, the retail price of pazopanib in China has dropped after the medical insurance negotiations. Common specifications include two packages of 200mg and 400mg. The market price of a box of 30 tablets of the 400mg specification is about RMB 3,000. The actual burden will be significantly reduced after medical insurance payment, which greatly eases the economic burden of medication. Some places still have registration or prescription qualification requirements for the use of this drug. Patients should consult the hospital doctor when using it for the first time to ensure that the medication process meets the medical insurance review standards. In addition, in parallel with the imported original drugs, there are also some overseas versions, such as the Bangladeshi generic version. The price may be as low as less than 1,000 yuan per box, and the drug ingredients are basically the same as the original drugs.

With the improvement of the domestic drug review system and the normalization of medical insurance negotiations, the accessibility and price of pazopanib are expected to be further optimized in the future. For eligible patients, standardizing medication through medical insurance channels is not only safer, but also significantly alleviates financial pressure.

Reference materials:https://www.votrient.com/